Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Grail’s multi-cancer blood test gets FDA breakthrough status

Grail’s multi-cancer blood test gets FDA breakthrough status

Jennifer Cook. “We’re excited the FDA recognises the potential of our multi-cancer early detection blood test. ... The results gathered from this trial will be used to inform, further develop and evaluate the blood test for early detection of

Latest news

More from news
Approximately 9 fully matching, plus 221 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities. ... This is an exciting and rewarding time to be working in blood cancer, with rapid clinical advances developing in

  • THE OTHER SIDE OF...BLOOD CANCER

    Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called  myelofibrosis. ... The environment  is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’s time is limited.

  • Therapy Watch expands oncology and IBD portfolios

    US. CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. ... Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's

  • New partnership with ELF in 2017

    The White Cell’ is an art installation that allows those affected by blood cancer to release their hidden thoughts and also show how the new ELF Mind and Body Service is

  • Frontera wins at IPA Best of Health 2016

    This art installation allows those affected by blood cancer to let out their hidden thoughts and see how the ELF Mind and Body Service is able to support them.  .

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics